The Utility of Preoperative Serum CA125 Combined with HE4 to Predict Lymph Node Metastasis in Endometrial Cancer

Objectives: To investigate the diagnostic performance of the serum cancer antigen 125 (CA125), human epididymis protein 4 (HE4), a combination of CA125 and HE4, and a Risk of Ovarian Malignancy Algorithm (ROMA) in the preoperative prediction of high-risk lymph node metastasis in patients with early-stage endometrial cancer (EC). Designs: This is a cross-sectional study Participants/Materials, Setting, and Methods: A cross-sectional study of data for patients with early-stage endometrioid EC treated surgically at Rajavithi Hospital between April 2020 and April 2021 was commenced. The preoperative serum levels of CA125 and HE4 were measured and analyzed. The ROC curves were generated to determine the optimal cutoff values of CA125, HE4, and ROMA with optimum sensitivity and specificity for predicting lymph node metastasis (LMN). Results: Eighty-six patients with surgically staged EC were identified. Lymph node involvement was detected in 9 patients (10.5%). The median serum CA125, HE4, and ROMA levels were significantly higher in EC patients having LMN than in those who did not (p
Source: Gynecologic and Obstetric Investigation - Category: OBGYN Source Type: research